GSK Plc ADR (GSK) concluded trading on Thursday at a closing price of $39.58, with 6.09 million shares of worth about $241.0 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 16.55% during that period and on July 10, 2025 the price saw a gain of about 1.38%. Currently the company’s common shares owned by public are about 2.04B shares, out of which, 2.02B shares are available for trading.
Stock saw a price change of 2.78% in past 5 days and over the past one month there was a price change of -3.13%. Year-to-date (YTD), GSK shares are showing a performance of 2.25% which increased to 17.03% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $31.72 but also hit the highest price of $44.67 during that period. The average intraday trading volume for GSK Plc ADR shares is 5.15 million. The stock is currently trading 1.02% above its 20-day simple moving average (SMA20), while that difference is up 1.39% for SMA50 and it goes to 6.60% higher than SMA200.
GSK Plc ADR (NYSE: GSK) currently have 2.04B outstanding shares and institutions hold larger chunk of about 18.16% of that.
The stock has a current market capitalization of $80.01B and its 3Y-monthly beta is at 0.51. PE ratio of stock for trailing 12 months is 20.55, while it has posted earnings per share of $1.93 in the same period. Its PEG reads 1.98 and has Quick Ratio of 0.58 while making debt-to-equity ratio of 1.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GSK, volatility over the week remained 1.55% while standing at 1.64% over the month.
Stock’s fiscal year EPS is expected to rise by 11.79% while it is estimated to increase by 11.75% in next year. EPS is likely to grow at an annualized rate of 10.36% for next 5-years, compared to annual growth of -11.63% made by the stock over the past 5-years.
Coverage by Exane BNP Paribas stated GSK Plc ADR (GSK) stock as a Neutral in their note to investors on April 15, 2025, suggesting a price target of $35.25 for the stock. Stock get a Hold rating from Jefferies on November 12, 2024.
